- Home
- AU vs BDX Comparison
AU vs BDX Comparison
Compare AU & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | BDX |
|---|---|---|
| Founded | 1944 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 51.5B |
| IPO Year | 2023 | 1997 |
Fundamental Metrics
Financial Performance| Metric | AU | BDX |
|---|---|---|
| Price | $78.05 | $148.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $119.00 | ★ $186.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.94% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $38.71 | N/A |
| Revenue Next Year | $2.89 | $3.02 |
| P/E Ratio | ★ $23.93 | $608.16 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $44.34 | $141.82 |
| 52 Week High | $129.14 | $213.08 |
Technical Indicators
Market Signals| Indicator | AU | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 49.25 |
| Support Level | $70.77 | $142.48 |
| Resistance Level | $79.94 | $150.74 |
| Average True Range (ATR) | 3.59 | 3.23 |
| MACD | -1.34 | 0.78 |
| Stochastic Oscillator | 2.14 | 52.89 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.